News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Muscle Drug Sales May Reach $4 Billion, According To MorphoSys AG


3/6/2014 7:31:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis AG (NOVN)’s muscle-building drug bimagrumab may reach as much as $4 billion in peak sales, according to the medicine’s co-developer. The forecast is for the use of the treatment, known as BYM338, in all indications, according to Simon Moroney, chief executive officer of MorphoSys AG (MOR), the company that developed the drug for Novartis. He spoke yesterday at an investor event in Munich. Novartis has said it plans to ask regulators for permission to market the drug to treat sporadic inclusion body myositis, a rare disease characterized by weakening muscles, as early as in 2016.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES